

Saad A Khan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4043220/publications.pdf>

Version: 2024-02-01

83
papers

3,011
citations

516710

16
h-index

175258

52
g-index

83
all docs

83
docs citations

83
times ranked

4966
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	13.7	1,804
2	Immune dysregulation in cancer patients developing immune-related adverse events. <i>British Journal of Cancer</i> , 2019, 120, 63-68.	6.4	126
3	Prevalence of Autoimmune Disease Among Patients With Lung Cancer. <i>JAMA Oncology</i> , 2016, 2, 1507.	7.1	121
4	Head and neck oncology during the COVID-19 pandemic: Reconsidering traditional treatment paradigms in light of new surgical and other multilevel risks. <i>Oral Oncology</i> , 2020, 105, 104684.	1.5	104
5	Clinical Practice in PET/CT for the Management of Head and Neck Squamous Cell Cancer. <i>American Journal of Roentgenology</i> , 2017, 209, 289-303.	2.2	103
6	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
7	Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. <i>Oncologist</i> , 2017, 22, 255-263.	3.7	60
8	A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). <i>Lung Cancer</i> , 2015, 89, 66-70.	2.0	52
9	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. <i>Oncology</i> , 2016, 90, 339-346.	1.9	43
10	Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the <i>In Vitro</i> Integrity of T Cells from Cancer Patients. <i>Clinical Cancer Research</i> , 2019, 25, 828-838.	7.0	37
11	Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 766-771.	1.3	32
12	Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1440168.	4.6	31
13	Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. <i>JAMA Oncology</i> , 2016, 2, 529.	7.1	26
14	Characterization of genetically complex Collaborative Cross mouse strains that model divergent locomotor activating and reinforcing properties of cocaine. <i>Psychopharmacology</i> , 2020, 237, 979-996.	3.1	25
15	Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. <i>Head and Neck</i> , 2019, 41, 1928-1934.	2.0	21
16	Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer. <i>Oncology</i> , 2020, 98, 179-185.	1.9	20
17	How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. <i>Lung Cancer</i> , 2018, 115, 97-102.	2.0	18
18	Risk of Unplanned Hospital Encounters in Patients Treated With Radiotherapy for Head and Neck Squamous Cell Carcinoma. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 738-745.e3.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Late-Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor-Induced Raynaud's-Like Phenomenon. <i>Oncologist</i> , 2020, 25, e753-e757.	3.7	17
20	Comparative effectiveness of induction chemotherapy for oropharyngeal squamous cell carcinoma: A population-based analysis. <i>Oral Oncology</i> , 2016, 54, 58-67.	1.5	16
21	Association between treatment delays and oncologic outcome in patients treated with surgery and radiotherapy for head and neck cancer. <i>Head and Neck</i> , 2019, 41, 315-321.	2.0	16
22	Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors. , 2021, 9, e002349.		16
23	Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. <i>International Journal of Endocrine Oncology</i> , 2016, 3, 221-233.	0.4	15
24	Safety and Efficacy of Andeciximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study. <i>Oncologist</i> , 2020, 25, 954-962.	3.7	14
25	Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2022, 23, 214-225.	2.6	14
26	National patterns of care and predictors of neoadjuvant and concurrent chemotherapy use with definitive radiotherapy in the treatment of patients with oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2017, 123, 273-282.	4.1	13
27	Activity and pharmacology of homemade silver nanoparticles in refractory metastatic head and neck squamous cell cancer. <i>Head and Neck</i> , 2018, 41, E11-E16.	2.0	13
28	Comparative effectiveness of primary radiotherapy versus surgery in elderly patients with locally advanced oropharyngeal squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 88, 18-26.	1.5	13
29	Survivin expression and impact on head and neck cancer outcomes. <i>Oral Oncology</i> , 2021, 112, 105049.	1.5	12
30	A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck. <i>Cancer Investigation</i> , 2017, 35, 23-31.	1.3	11
31	Race- and Sex-Based Disparities in the Therapy and Outcomes of Squamous Cell Carcinoma of the Anus. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 998-1004.	4.9	10
32	Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition?. <i>Oncologist</i> , 2020, 25, e1242-e1245.	3.7	10
33	Relationship of anaplastic thyroid cancer high tumor mutation burden and MSI-H status with response to anti-PD1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e18114-e18114.	1.6	9
34	Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab. <i>Head and Neck</i> , 2017, 39, E69-E71.	2.0	8
35	Patterns of Care and Comparative Effectiveness of Intensified Adjuvant Therapy for Resected Oropharyngeal Squamous Cell Carcinoma in the Human Papillomavirus Era. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 777.	2.2	7
36	Risk of contralateral nodal failure following ipsilateral IMRT for node-positive tonsillar cancer. <i>Oral Oncology</i> , 2017, 75, 35-38.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Genomic Analysis of Salivary Gland Cancer and Treatment of Salivary Gland Cancers. <i>Surgical Pathology Clinics</i> , 2021, 14, 151-163.	1.7	6
38	Comprehensive genomic profiling of anaplastic thyroid carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 6089-6089.	1.6	5
39	A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. <i>Investigational New Drugs</i> , 2022, 40, 782-788.	2.6	5
40	Head and neck neuroendocrine tumors at a single institution over 15 years. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 2508-2512.	0.5	4
41	Phase II trial of carboplatin/paclitaxel and cetuximab, followed by carboplatin/paclitaxel/cetuximab and erlotinib, in metastatic or recurrent squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6027-6027.	1.6	4
42	A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS6105-TPS6105.	1.6	4
43	Experimental approaches in the treatment of multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2011, 2, 213-230.	2.5	3
44	NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS6093-TPS6093.	1.6	3
45	Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , 2019, 18, A088-A088.	4.1	3
46	Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001).. <i>Journal of Clinical Oncology</i> , 2022, 40, 3094-3094.	1.6	3
47	Anesthetic management for a patient with medium-chain acyl-CoA dehydrogenase deficiency in an outpatient setting using ketamine and fentanyl. <i>Journal of Clinical Anesthesia</i> , 2019, 56, 45-46.	1.6	2
48	Therapy with tyrosine kinase inhibitor lenvatinib in radioactive iodine-naive advanced differentiated thyroid cancer. <i>International Journal of Endocrine Oncology</i> , 2019, 6, ije23.	0.4	2
49	Comparative cost analysis between definitive radiotherapy and transoral surgery for oropharyngeal squamous cell carcinoma: A SEER-Medicare analysis. <i>Oral Oncology</i> , 2021, 112, 105029.	1.5	2
50	Extracapsular extension, pathologic node status, and adjuvant treatment in primary surgery patients with human papillomavirus-mediated oropharyngeal cancer: National hospital-based retrospective cohort analysis. <i>Head and Neck</i> , 2021, 43, 3345-3363.	2.0	2
51	Genomic profiling of squamous malignancies across anatomic sites.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11512-11512.	1.6	2
52	Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS6098-TPS6098.	1.6	2
53	Racial and gender disparities in therapy and outcomes of squamous cell cancer of the anus.. <i>Journal of Clinical Oncology</i> , 2017, 35, 691-691.	1.6	2
54	Racial and sex disparities in changing trends of squamous cell cancer of the anus (SSCA).. <i>Journal of Clinical Oncology</i> , 2016, 34, 520-520.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Prevalence and usage patterns of opiates in patients with lung, breast, and head and neck cancer.. Journal of Clinical Oncology, 2018, 36, 120-120.	1.6	2
56	Clinical Role of Positron Emission Tomography/Computed Tomography Imaging in Head and Neck Squamous Cell Carcinoma. PET Clinics, 2022, 17, 213-222.	3.0	2
57	Anesthetic considerations for a patient with myasthenia gravis undergoing deep sedation in an outpatient oral surgery setting. Journal of Dental Anesthesia and Pain Medicine, 2019, 19, 67.	1.0	1
58	Perspective-Based Surgical Videography in Private Practice: Pros, Cons, and Where to Improve. Surgical Innovation, 2020, 27, 412-413.	0.9	1
59	Efficacy and Safety of Clembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504). JTO Clinical and Research Reports, 2021, 2, 100166.	1.1	1
60	Patterns of distant metastases in HPV-positive head and neck squamous cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 6071-6071.	1.6	1
61	Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC).. Journal of Clinical Oncology, 2016, 34, 6014-6014.	1.6	1
62	Neuroendocrine tumors of the head and neck: SEER analysis of survival and incidence.. Journal of Clinical Oncology, 2015, 33, e17051-e17051.	1.6	1
63	Minimizing the risk of perioperative cardiovascular complications in homozygous familial hypercholesterolemia: a case report. Journal of Dental Anesthesia and Pain Medicine, 2020, 20, 39.	1.0	1
64	Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients.. Journal of Clinical Oncology, 2020, 38, e21571-e21571.	1.6	1
65	Use of 18-FDG PET in Determination of Disease Extent in HPV/p16-Positive Oropharyngeal Squamous Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2014, 90, S519-S520.	0.8	0
66	2813 Comprehensive genomic profiling of clinically advanced medullary thyroid carcinoma. European Journal of Cancer, 2015, 51, S562.	2.8	0
67	Confluent tracheal recurrences of head and neck squamous cell carcinoma. Clinical Case Reports (discontinued), 2019, 7, 1849-1853.	0.5	0
68	Analysis of opioid and adjunctive pain medication prescriptions in lung cancer patients.. Journal of Clinical Oncology, 2021, 39, e24073-e24073.	1.6	0
69	Risk factors for ED visits and admissions during outpatient chemotherapy in head and neck cancer.. Journal of Clinical Oncology, 2021, 39, 223-223.	1.6	0
70	Ceritinib in anaplastic thyroid cancer (ATC) with ALK abnormalities.. Journal of Clinical Oncology, 2015, 33, TPS6085-TPS6085.	1.6	0
71	Prevalence of autoimmune conditions among patients with lung cancer: Implications for immunotherapy treatment options.. Journal of Clinical Oncology, 2016, 34, 9039-9039.	1.6	0
72	Comparative effectiveness of primary radiotherapy versus surgery in oropharyngeal squamous cell carcinoma in elderly patients: A SEER-Medicare analysis.. Journal of Clinical Oncology, 2017, 35, e18124-e18124.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials.. Journal of Clinical Oncology, 2017, 35, 9051-9051.	1.6	0
74	In-human activity and pharmacology of homemade silver nanoparticles in highly refractory metastatic head and neck squamous cell cancer.. Journal of Clinical Oncology, 2017, 35, e17533-e17533.	1.6	0
75	Abstract 3660: Blocking the DC-HIL receptor reverses the T-cell suppression induced by proliferating myeloid-derived suppressor cells in common cancer types. , 2017, , .		0
76	Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients.. Journal of Clinical Oncology, 2017, 35, 114-114.	1.6	0
77	Underlying host immune dysregulation in cancer patients developing immune-related adverse events.. Journal of Clinical Oncology, 2018, 36, 3030-3030.	1.6	0
78	Risk of gastrointestinal and hepatic toxicities in patients with advanced breast cancer treated with everolimus: A meta- analysis of phase 3 randomized controlled trials.. Journal of Clinical Oncology, 2018, 36, e22215-e22215.	1.6	0
79	Evaluating sociodemographic, behavioral and psychologic disparities in 918 head and neck cancer survivors.. Journal of Clinical Oncology, 2019, 37, e17541-e17541.	1.6	0
80	Association of electronic medical record (EMR) QTc alerts with higher mortality within 10 days for patients with blood, lung, GI, and soft tissue cancer.. Journal of Clinical Oncology, 2019, 37, 235-235.	1.6	0
81	Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy.. Journal of Clinical Oncology, 2020, 38, e15126-e15126.	1.6	0
82	Preventable patient acute mortality after EMR-generated QTc alerts.. Journal of Clinical Oncology, 2020, 38, e19359-e19359.	1.6	0
83	Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy.. Journal of Clinical Oncology, 2020, 38, 3043-3043.	1.6	0